申请人:ELI LILLY AND COMPANY
公开号:EP0921120A1
公开(公告)日:1999-06-09
The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective b3 receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and methods of treating type II diabetes and obesity, comprising administering to a mammal in need thereof compounds of the Formula I:
wherein:
X1 is -OCH2-, -SCH2-, or a bond;
R1 is a heterocycle of the formula:
R2 and R3 are independently hydrogen, C1-C4 alkyl, or aryl;
R4 is an optionally substituted heterocycle or a moiety selected from the group consisting of:
X2 is a bond, or a 1 to 5 carbon straight or branched alkylene;
R5 is hydrogen or C1-C4 alkyl;
R6 is hydrogen or C1-C4 alkyl;
or R5 and R6 combine with the carbon to which each is attached to form a C3-C6 cycloalkyl;
or R6 combines with X2 and the carbon to which each is attached to form a C3-C8 cycloalkyl;
or R6 combines with X2, R4, and the carbon to which each is attached to form:
provided that R5 is hydrogen;
R7 is hydrogen, hydroxy, cyano, oxo, COnR2, CONHR2, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 optionally substituted alkyl, (CH2)n aryl, (CH2)nheterocycle, (CH2)n optionally substituted aryl, or (CH2)n optionally substituted heterocycle;
R8 is independently hydrogen, halo, or C1-C4 alkyl;
R9 is halo, CN, OR10, C1-C4 alkyl, C1-C4 haloalkyl, CO2R2, CONR11R12, CONH(C1-C4 alkyl or C1-C4 alkoxy), SR2, CSNHR2, CSNR11R12, SO2R2, SOR2, NR11R12, optionally substituted aryl, optionally substituted heterocycle, or C2-C4 alkenyl substituted with CN, CO2R2, or CONR11R12;
R10 is C1-C4 alkyl, C1-C4 haloalkyl, (CH2)nC3-C8 cycloalkyl, (CH2)naryl, (CH2)nheterocycle, (CH2)nC3-C8 optionally substituted cycloalkyl, (CH2)n optionally substituted aryl, or (CH2)n optionally substituted heterocycle;
R11 and R12 are independently hydrogen, C1-C4 alkyl, aryl, (CH2)naryl, or combine with the nitrogen to which each is bound to form morpholinyl, piperidinyl, pyrrolidinyl, or piperazinyl;
R13 is hydrogen, halo, aryl, or C1-C4 alkyl;
m is 0 or 1;
n is 0, 1, 2, or 3;
or a pharmaceutically acceptable salt thereof.
本发明属于医学领域,特别是 II 型糖尿病和肥胖症的治疗。更具体地说,本发明涉及用于治疗 II 型糖尿病和肥胖症的选择性 b3 受体激动剂。本发明提供了治疗 II 型糖尿病和肥胖症的化合物和方法,包括向需要的哺乳动物施用式 I 的化合物:
其中
X1是-OCH2-、-SCH2-或键;
R1 是式中的杂环:
R2 和 R3 独立地为氢、C1-C4 烷基或芳基;
R4 是任选取代的杂环或选自以下组成的组的分子:
X2 是键,或 1 至 5 碳直链或支链亚烷基;
R5 是氢或 C1-C4 烷基
R6 是氢或 C1-C4 烷基;
或 R5 和 R6 与各自相连的碳结合形成 C3-C6 环烷基;
或 R6 与 X2 和各自相连的碳结合形成 C3-C8 环烷基;
或 R6 与 X2、R4 和各自相连的碳结合形成:
但 R5 为氢;
R7 是氢、羟基、氰基、氧代、COnR2、CONHR2、C1-C4 烷基、C1-C4 烷氧基、C1-C4 卤代烷基、C1-C4 任选取代的烷基、(CH2)n 芳基、(CH2)n 杂环、(CH2)n 任选取代的芳基或 (CH2)n 任选取代的杂环;
R8 独立地为氢、卤代或 C1-C4 烷基;
R9 是卤素、CN、OR10、C1-C4 烷基、C1-C4 卤代烷基、CO2R2、CONR11R12、CONH(C1-C4 烷基或 C1-C4 烷氧基)、SR2、CSNHR2、CSNR11R12、SO2R2、SOR2、NR11R12、任选取代的芳基、任选取代的杂环或被 CN、CO2R2 或 CONR11R12 取代的 C2-C4 烯基;
R10 是 C1-C4 烷基、C1-C4 卤代烷基、(CH2)nC3-C8 环烷基、(CH2)n 芳基、(CH2)n 异环、(CH2)nC3-C8 任选取代的环烷基、(CH2)n 任选取代的芳基或 (CH2)n 任选取代的杂环;
R11 和 R12 独立地为氢、C1-C4 烷基、芳基、(CH2)芳烷基,或与各自结合的氮结合形成吗啉基、哌啶基、吡咯烷基或哌嗪基;
R13 是氢、卤代、芳基或 C1-C4 烷基;
m 是 0 或 1;
n 是 0、1、2 或 3;
或其药学上可接受的盐。